Analytical evidence
Epitalon vs Epithalamin: Two Different Material Descriptions
Separate Epitalon and Epithalon spelling variants from Epithalamin, an extracted polypeptide complex, before comparing laboratory materials.
In this guide · 6 sections
The short answer
Epitalon and Epithalon can name the same four-residue peptide. Epithalamin describes a different material: a polypeptide complex extracted from the pineal gland. A laboratory purchasing record should preserve that distinction rather than merge all three names into one synonym list.
This guide explains material identity for laboratory research procurement. It provides no preparation instructions or basis for human or veterinary use.
The useful comparison is therefore between a defined peptide and an extracted complex. First establish which material the work requires. Then resolve the exact chemical form and the evidence attached to the offered lot.
Which names can be grouped together?
Epitalon and Epithalon are spelling variants used for the tetrapeptide Ala-Glu-Asp-Gly, also abbreviated AEDG. Epithalamin should remain a separate material description. Epithalamin's relationship to the development of Epitalon does not make the extract and the tetrapeptide equivalent materials.
For a search, alternate spellings help find records. For an inventory system, they need a narrower role. Keep the supplier's original name, and add an alias only after checking what the underlying record describes. Otherwise a convenient search feature can erase a material distinction that the laboratory needs to retain.
| Name encountered | Material description | Purchasing implication |
|---|---|---|
| Epitalon | The defined tetrapeptide Ala-Glu-Asp-Gly | Obtain the chemical form and lot-specific documentation |
| Epithalon | A spelling variant used for Epitalon | Check that the supplier's structural description matches |
| AEDG | One-letter shorthand for the four-residue sequence | Preserve any terminal, stereochemical and salt-form details separately |
| Epithalamin | An extracted polypeptide complex | Request a description of the preparation and its composition |
The table is a naming aid. It does not establish what an unexamined product contains.
A defined peptide and an extract need different descriptions
For a defined peptide, the central question is whether the offered material corresponds to the required chemical structure. A sequence is a starting point; the specification can also identify the termini, residue configuration and supplied form.
For an extracted complex, the central question is what preparation is being supplied and how that preparation is characterised. Calling it an extract does not tell the purchaser its complete composition, relative component amounts, processing history or consistency between lots. Those are questions for the preparation's own documentation.
This changes the comparison itself. An AEDG identity result and an extract-composition description answer different questions. Even if a component is detected within an extract, that observation would not establish that the whole extract is equivalent to an isolated preparation of that component.
Consider a requisition that specifies a defined AEDG material. A quotation described only as an Epithalamin preparation leaves the original requirement unmet. The next step is to obtain the offered preparation's definition or correct the quotation. It would be premature to compare the quotations by nominal milligrams or headline purity because the requested material has not yet been matched.
Conversely, if a laboratory intentionally requires a characterised extract, replacing it with a single synthetic peptide would change the material under investigation. A closely related name is insufficient authority for that substitution.
What AEDG tells you, and what it leaves open
The identification section of Cayman Chemical's Epitalon safety data sheet gives Ala-Glu-Asp-Gly and the formal name L-alanyl-L-α-glutamyl-L-α-aspartyl-glycine, trifluoroacetate salt. This identifies both the peptide and a stated salt form. The one-letter sequence is AEDG. Cayman Chemical safety data sheet, item 39177
Read such a record in layers:
The sequence identifies the order of the amino-acid residues.
The expanded chemical name or structure supplies details that abbreviated letters may omit.
The stated salt form describes an additional part of the supplied-material specification.
The manufacturer's item number identifies that particular catalogue entry.
Do not transfer the trifluoroacetate designation from this reference product to another supplier's Epitalon. Nor should a missing salt field be filled automatically with acetate or a salt-free designation. The absence is a question to resolve with the supplier.
This is particularly important when copying chemical information between systems. A common name may appear unchanged while a form qualifier disappears from a spreadsheet, purchase order or laboratory submission. Preserve the fuller identity wording in the material record even if a shorter display name is needed elsewhere.
How this applies to Peptide Confidential's Epitalon record
The Epitalon product page links to its published certificate. The certificate for lot ET-GZ-081826 identifies the submitted compound as Epitalon and includes compound-identification and analytical-result fields. It does not describe the sample as an Epithalamin extract. Published certificate for ET-GZ-081826
The product page also distinguishes its summary from the fuller certificate. That matters here: a product name, a transcribed result and a complete material specification are separate pieces of information. The report's Epitalon identification should be read as the report's finding for its sample; it should not be expanded into a claim that every possible identity attribute was independently established.
If a project requires a particular salt or terminal form, ask for that specification explicitly. Neither the similar spelling of another preparation nor an external manufacturer's catalogue can supply an omitted field for this lot. Use the lab-results index to locate the applicable record when the lot changes.
Resolve the naming question before approving a substitution
A practical decision can be recorded in three short statements:
Material required: state whether the project needs a defined AEDG peptide or an extracted preparation, with the required form or preparation specification.
Material offered: preserve the supplier's exact designation and attach the document that defines it.
Relationship established: record whether the documents describe the same required material, different materials, or an unresolved match.
An unresolved match is useful information. It tells procurement exactly what to ask instead of forcing a yes-or-no answer from a name alone. A focused question might be: “Does this quotation describe a defined AEDG peptide or an extracted polypeptide preparation, and which document defines the supplied form?”
The same question works for a Canadian purchase order or a cross-border laboratory quotation. Geography does not resolve a chemical naming ambiguity, and a locally familiar product name should not replace the material description.
For the broader distinction between analytical identity and other reported measurements, see Peptide Purity, Identity and Content Explained. For this comparison, the decisive first step is simpler: keep the spelling variants together only where the structure supports them, and keep Epithalamin's extract description separate.
Sources and scope
The safety data sheet is cited only for how one manufacturer identifies its own item. The naming table and the three-statement record are original editorial tools; neither establishes what an unexamined product contains.
Published by Peptide Confidential, a commercial supplier of research materials. Apply these checks to our documentation as well as another supplier's.